Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 6/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.40 |
| ▸ | CCNK | O75909 | 7/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.40 |
| ▸ | CDK2 | P24941 | 7/20 | 0.40 |
| ▸ | CDK9 | P50750 | 7/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 7/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.39 |
| ▸ | CDK7 | P50613 | 5/20 | 0.39 |
| ▸ | CCNH | P51946 | 4/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.39 |
| ▸ | PRKCI | P41743 | 2/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14183781 | 0.86 | KMT2A (0.49) | — | |
| SCHEMBL6306635 | 0.86 | KMT2A (0.46) | — | |
| SCHEMBL5439050 | 0.85 | KMT2A (0.51) | — | |
| SCHEMBL183228 | 0.85 | KMT2A (0.51) | — | |
| SCHEMBL5442344 | 0.85 | KMT2A (0.51) | — | |
| SCHEMBL29684584 | 0.84 | IKBKB (0.39) | BRD4AURKARPS6KB1 | |
| SCHEMBL7111201 | 0.83 | ADORA3 (0.41) | — | |
| SCHEMBL16013820 | 0.80 | BTK (0.44) | — | |
| SCHEMBL4764723 | 0.79 | ADORA3 (0.44) | — | |
| SCHEMBL2953695 | 0.79 | ADORA3 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | CHEK1 2783/4885BRD4 1297/4885CCNT1 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.